Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867013 | 0.79 | CTPS1 (0.42) | LMNANR3C1KEAP1HTT | |
| SCHEMBL5867011 | 0.79 | CTPS1 (0.42) | LMNANR3C1KEAP1HTT | |
| SCHEMBL5867090 | 0.79 | IDO1 (0.52) | IDO1LMNA | |
| SCHEMBL5935553 | 0.78 | LMNA (0.53) | IDO1LMNAHTT | |
| SCHEMBL5866943 | 0.74 | KCNQ2 (0.43) | IDO1LMNAHTT | |
| SCHEMBL6777820 | 0.73 | KEAP1 (0.40) | LMNANR3C1KEAP1PGRNR3C2 | |
| SCHEMBL5866921 | 0.73 | IDO1 (0.62) | IDO1LMNA | |
| SCHEMBL5866888 | 0.70 | LMNA (0.52) | IDO1LMNACRHR1 | |
| SCHEMBL5866857 | 0.69 | IDO1 (0.58) | IDO1 | |
| SCHEMBL5866850 | 0.67 | LMNA (0.62) | IDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148259-B1 | Antibacterial agents | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7053234-B2 | Antibacterial agents | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | TULARIK INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | HNMT, HDHD5, ABCC1 | IDO1 3464/4885LMNA 4115/4885CRHR1 4539/4885 |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | IDO1 3821/4885LMNA 4203/4885CRHR1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.